SCHEMBL14856486

SCHEMBL14856486

Cc1cc(C)cc(C(=O)N[C@H]2CCCNC(=O)C2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.50
TAS1R3 Q7RTX0 3/20 0.48
TAS1R1 Q7RTX1 3/20 0.48
TAS1R2 Q8TE23 3/20 0.48
RAB9A P51151 7/20 0.47
NPC1 O15118 5/20 0.47
SMN1; SMN2 Q16637 2/20 0.44
CYP1A2 P05177 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
MAPK1 P28482 1/20 0.44
OPRK1 P41145 1/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
GRM5 P41594 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
SMYD3 Q9H7B4 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GFER P55789 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14856186 1.00 POLB (0.50) POLBTAS1R3TAS1R1TAS1R2RAB9A
SCHEMBL8312276 0.86 RAB9A (0.62) RAB9ANPC1SMN1; SMN2CYP1A2HPGD
SCHEMBL14856022 0.86 RAB9A (0.62) RAB9ANPC1SMN1; SMN2CYP1A2HPGD
SCHEMBL9205578 0.82 MAPK1 (0.68) POLBMAPK1OPRK1MEN1KMT2A
SCHEMBL8313165 0.81 MAOB (0.47) RAB9ANPC1SMN1; SMN2CYP1A2HPGD
SCHEMBL8313089 0.79 NPC1 (0.46) RAB9ANPC1SMN1; SMN2CYP1A2HPGD
SCHEMBL8311437 0.79 KMT2A (0.52) MAPK1OPRK1MEN1KMT2AALDH1A1
SCHEMBL8313720 0.78 NPC1 (0.52) RAB9ANPC1SMN1; SMN2HPGDMEN1
SCHEMBL9200588 0.78 NPC1 (0.52) RAB9ANPC1SMN1; SMN2HPGDMEN1
SCHEMBL14856753 0.78 RAB9A (0.69) POLBTAS1R3TAS1R1TAS1R2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130172318-A1 ANTI-INFLAMMATORY AGENTS GRAINGER DAVID JOHN (GB) 2013-07-04 US claimed
EP-2580196-A1 ANTI-INFLAMMATORY AGENTS Cambridge Enterprise Ltd. (GB) 2013-04-17 EP claimed
WO-2011154696-A1 ANTI-INFLAMMATORY AGENTS CAMBRIDGE ENTERPRISE LIMITED (GB) 2011-12-15 WO claimed
US-20130172318-A1 ANTI-INFLAMMATORY AGENTS GRAINGER DAVID JOHN (GB) 2013-07-04 US disclosed
EP-2580196-A1 ANTI-INFLAMMATORY AGENTS Cambridge Enterprise Ltd. (GB) 2013-04-17 EP disclosed
WO-2011154696-A1 ANTI-INFLAMMATORY AGENTS CAMBRIDGE ENTERPRISE LIMITED (GB) 2011-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172318-A1 ANTI-INFLAMMATORY AGENTS IL6, TNF, IL1B POLB 3544/4885TAS1R3 563/4885TAS1R1 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.